Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel, Cisplatin, and 5-FU in SCCHN
NCT00139269Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 1998
- Primary completion
- Dec 2006
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Acceptable Side Effects and Efficacy of Combination. Started Feb 1998; status: completed.
02
Drugs
docetaxel
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00139269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00139269.